Drugs.com Clinical Trial ResultsOriginal article
Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy
Data ReadoutpositiveIslatravirLenacapavirPositive
AI Analysis
Summary
Gilead Sciences and Merck announced positive Phase 3 results for an investigational once-weekly oral HIV treatment combining Islatravir and Lenacapavir, demonstrating maintained virological suppression in adults who switched antiretroviral therapy.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Once-weekly oral HIV treatment regimen maintained virological suppression in adults with HIV who switched antiretroviral therapy
Importance:7/10
Sentiment:
0.75
HIVantiretroviral therapyvirological suppressiononce-weeklyoral regimen
Read the original article
Published by Drugs.com Clinical Trial Results on July 21, 2026 8:07 PM